Inclusion Criteria:

- Acute Myeloid leukemia with a FLT3-ITD who are in a complete remission or partial
remission(less than 10% blasts in marrow) as documented by bone marrow biopsy and who
plan to undergo a bone marrow transplantation

- Patients who have had count recovery (ANC over 500, non transfused platelet count
over 50) and are at least 30 days after induction and/or transplantation but no more
than 120 days post transplant

- Patients may have received any prior therapy deemed necessary for induction of
remission except for patients whom have progressed while on sorafenib; patients who
have responded to sorafenib previously are eligible for enrollment on the protocol

- ECOG performance status =< 2 (Karnofsky >= 60%)

- Life expectancy of greater than four months

- Total bilirubin less than 2x upper limit of normal

- AST(SGOT)/ALT(SGPT) =< 5 X institutional upper limit of normal

- Creatinine within normal institutional limits OR creatinine clearance >= 60
mL/min/1.73 m^2 for patients with creatinine levels above institutional normal

- Women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry and
for the duration of study participation; should a woman become pregnant or suspect
she is pregnant while participating in this study, she should inform her treating
physician immediately; contraception should continue for at least 30 days after the
last dose of sorafenib

- Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

- Patients who have had chemotherapy or radiotherapy within 2 weeks except for
intrathecal chemotherapy(ie Methotrexate, Cytarabine, or Thiotepa)

- Patients may not be receiving any other investigational agents

- Patients with uncontrolled hypertension(ie, persistent grade 3 while undergoing
treatment)

- Patients with active and/or untreated CNS leukemia will not be eligible

- Patients must not have any evidence of bleeding diathesis or be on any therapeutic
anticoagulation such as LMW heparin or warfarin for DVT treatment

- Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements

- Pregnant women are excluded from this study because sorafenib is chemotherapeutic
agent with the potential for teratogenic or abortifacient effects; because there is
an unknown but potential risk for adverse events in nursing infants secondary to
treatment of the mother with sorafenib, breastfeeding should be discontinued if the
mother is treated sorafenib

- HIV-positive patients are excluded because management of these patients in the
hematopoietic cell transplant setting has not yet been well defined and is currently
the subject of investigation in other studies addressing this issue

- Patients with active acute GVHD who have been initiated on therapy or had therapy
escalation within 21 days are not eligible

- Patients with lack of engraftment(less than 90% donor DNA in bone marrow or
peripheral blood) after bone marrow transplant as evidence by RFLP(restriction
fragment length polymorphism) are not eligible

- Patients who are unable to swallow pills are not eligible

- Patients taking strong CYP3A4 inhibitors including enzyme-inducing anti-epileptic
drugs (phenytoin, carbazepine, or phenobarbitol), rifampin, grape fruit juice, or St.
Johns Wort are not eligible